Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Tripeptide wrinkle-reducing compound containing 3,4-dehydro-L-proline residue as well as preparation method and application thereof

A compound and composition technology, applied in the field of tripeptide anti-wrinkle compounds and their preparation, can solve the problems of failing to show wrinkle-reducing effect, failing to show clinical applicability and the like

Inactive Publication Date: 2015-05-06
张嘎
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Chinese patent 200580039359.9 discloses a tripeptide compound with a more simplified structure, in which compounds 4.5 and 4.6 showed better wrinkle-reducing effects than ajirelin at 2 hours and 48 hours in the cell-level test, but their It failed to show satisfactory wrinkle reduction effects in longer wrinkle reduction experiments, and failed to show better clinical applicability in human trial tests

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Tripeptide wrinkle-reducing compound containing 3,4-dehydro-L-proline residue as well as preparation method and application thereof
  • Tripeptide wrinkle-reducing compound containing 3,4-dehydro-L-proline residue as well as preparation method and application thereof
  • Tripeptide wrinkle-reducing compound containing 3,4-dehydro-L-proline residue as well as preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0059] Example 1: Preparation of H—(β-Ala)—(3,4-Dehydro-Pro)—Dab—NH—Bzl and its acetate.

[0060] 1) Preparation of Fmoc-Dab(Boc)-2-Cl-Trt resin.

[0061] Weigh 8g (8.8mmol) of 2-Cl-Trt resin and 3.88g (8.8mmol) of Fmoc-Dab(Boc)-OH, and add it into a ground-mouthed round bottom flask, then add DIPEA15.7ml (88mmol) and DCM80ml , Shake well, seal and shake on a shaker for 18 hours. Wash the resin with DMF, then add 85ml of DCM, 10ml of methanol and 5ml of DIPEA to block for 20min. After blocking, the resin was washed four times with DMF (60ml) and twice with DCM (60ml). Aspirate the solution. Shrink the resin three times with 60ml, 30ml and 30ml methanol respectively. Vacuum dry. Weighs 9.1g. Store in dry and low temperature. As determined by FMOC absorption method, the amino acid substitution amount is 0.65mmol / gram of resin.

[0062] 2) Preparation of H-Dab(Boc)-2-Cl-Trt resin.

[0063] Weigh 9.1 g of dry Fmoc-Dab(Boc)-2-Cl-Trt resin into a solid-phase reaction synth...

Embodiment 2

[0084] Example 2 In vitro model testing.

[0085] 1) Materials.

[0086] Normal human muscle cells (myoblasts) at the third passage

[0087] Spinal cord explants of 13-day-old rat embryos with "dorsal root ganglia"

[0088] Medium: 2 / 3MEM and 1 / 3M199, 2mML-glutamine, 50UI / ml penicillin, 50μg / ml streptomycin, 5% fetal bovine serum

[0089] Culture conditions: 37°C, 5% CO 2 .

[0090] 2) Test method.

[0091] To test the efficacy of the compounds of the present invention, a co-culture model of human myocytes and neurons from the spinal cord of rat embryos was established.

[0092] Normal human muscle cells (myoblasts) are cultured in gelatin-coated 24-well plates until a monolayer of myofibrils (from confluent myocytes) forms. Spinal cord explants of 13-day-old rat embryos with dorsal root ganglia were then placed on the myocyte monolayer. After 1 day of co-culture, the first neurite outgrowth from the explant was visible in contact with the myocyte. The first contract...

Embodiment 3

[0099] Example 3 Formulation of the composition.

[0100] 1) Preparation of ointment

[0101] .

[0102] Preparation steps: Heat raw material A (ie, compounds No. 1 to 5) to 70°C. Starting material B (ie, compounds Nos. 6 and 7) was heated to 75°C. Add raw material B to raw material A under stirring condition, cool to 50°C, homogenize and cool to 30°C. Then, raw material component C (ie, compounds No. 8 and 9) and raw material D (ie, compound hydrochloride of Example 1 of the present invention) were added in sequence, and stirred evenly.

[0103] 2) Preparation of gel

[0104] .

[0105] Preparation steps: Dissolve the raw materials numbered 2 to 6 in deionized water in sequence. Then adjust the pH to 6.0 with NaOH, and finally add the compound acetate of Example 1, and stir evenly.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
lengthaaaaaaaaaa
Login to View More

Abstract

The invention provides a tripeptide wrinkle-reducing compound containing 3,4-dehydro-L-proline residue and / or a salt formed by the tripeptide compound and acid. A structural formula of the tripeptide compound is as shown in the description and has short for H-(beta-Ala)-(3,4-Dehydro-Pro)-Dab-NH-Bzl, wherein beta-Ala refers to beta-alanine residue, 3,4-Dehydro-Pro refers to 3,4-dehydroproline residue with an L-shaped structure, Dab refers to L-2,4diamido butyrate residue, and Bzl refers to benzyl. The tripeptide wrinkle-reducing compound and / or the salt formed by the tripeptide compound and acid can be anacetylcholine receptor inhibitor which can loosen muscles, is remarkable in wrinkle-reducing effect and can be used for drug research and treatment for relieving and reducing wrinkles.

Description

technical field [0001] The invention belongs to the technical field of medicinal cosmetics, and specifically relates to a tripeptide wrinkle-reducing compound containing 3,4-dehydro-L-proline residues, a preparation method and application thereof. Background technique [0002] The formation of wrinkles is mainly caused by the strong contraction of muscles or the maintenance of muscles in a strongly contracted position for a long time. [0003] Currently, the main method of treating facial wrinkles is injection of botulinum toxin A, which paralyzes the facial muscles by injecting botulinum toxin A into the facial muscles. In this way, the muscles located in the eyes or forehead can no longer move, making eye or forehead wrinkles less likely to appear. However, the treatment with subcutaneous injection of botulinum toxin A must be implemented by professional doctors, and the high cost and high toxicity associated with it also limit the wide application of botulinum toxin A. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K5/023C07K1/06C07K1/04A61K38/06A61K8/64A61P17/00A61Q19/08
Inventor 张嘎张贲
Owner 张嘎
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com